Key facts
- Sigrid Therapeutics’s last known valuation is $40.5M (Oct 2023).
- It has raised $20.9M; the latest was Later Stage VC ($5.0M) in Jan 2026.
- Notable investors include Almi Invest, Joyance Partners, European Regional Development Fund (Brandenburg), Mattsson Family, The Hans and Barbara Bergström — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Sigrid Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sigrid Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sigrid Therapeutics
Operator of a clinical-stage biotechnology company intended to develop a new class of therapies to prevent and treat lifestyle diseases. The company has developed a novel materials platform technology that targets lifestyle diseases by altering the way the body digests food, and the product is the first therapy acting in the gut to improve blood sugar levels in individuals at risk of developing diabetes, helping patients prevent and treat modern-day chronic diseases.
- Sector
- Healthcare
- HQ
- Sundbyberg, Sweden
- Founded
- 2014
- Employees
- 17
- Website
- sigridthx.com/
- Ownership
- Privately Held (backing)
Sigrid Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sigrid Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sigrid Therapeutics in its N-PORT filings yet. We sweep new filings monthly.